Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||01/06/2018|
|Rapid review completed||22/06/2018|
|Rapid Review outcome||A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of pertuzumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||27/06/2018|